首页> 美国卫生研究院文献>BMC Cancer >Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study

【2h】

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study

机译：局部研究表明厄立布林对局部晚期或转移性乳腺癌患者的疗效和安全性不符合试验入选标准：一项回顾性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer has been demonstrated in phase III trials. However, as patients receiving eribulin in daily practice do not necessarily meet all the eligibility criteria of clinical trials, data for such patients are limited.

机译：背景III期临床试验已证明了eribulin对局部晚期或转移性乳腺癌患者的疗效和安全性。但是，由于每天接受eribulin的患者不一定符合临床试验的所有入选标准，因此此类患者的数据有限。

著录项

期刊名称 BMC Cancer
作者
Sakura Iizumi; Tatsunori Shimoi; Natsuko Tsushita; Seiko Bun; Akihiko Shimomura; Emi Noguchi; Makoto Kodaira; Mayu Yunokawa; Kan Yonemori; Chikako Shimizu; Yasuhiro Fujiwara; Kenji Tamura;
展开▼
作者单位

展开▼
年(卷),期 2017(17),-1
年度 2017
页码 819
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Breast cancer Eribulin Efficacy Safety;

机译：乳腺癌;依立布林;功效;安全性;

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study [J] . Sakura Iizumi, Tatsunori Shimoi, Natsuko Tsushita, BMC Cancer . 2017,第1期

机译：厄立布林在局部晚期或转移性乳腺癌患者中不符合试验入选标准的疗效和安全性：一项回顾性研究
3. International, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：国际，第3阶段试验：Balixafortide（CXCR4拮抗剂）加二林蛋白与Eribulin单独服用Her2阴性，局部复发或转移性乳腺癌（堡垒）国际，第3阶段试验：Balixafortide（A CXCR4拮抗剂）加二林蛋白与二林林单独相反 HER2阴性，局部复发或转移性乳腺癌（堡垒）的患者
4. A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT study) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：多中心，随机的，期间试验评估Eribulin单疗法和Eribulin加内分泌治疗在内分泌治疗后局部复发性或转移性乳腺癌患者的疗效（恢复研究）
5. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
6. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
7. Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study [O] . Junichiro Watanabe, Yoshinori Ito, Shozo Ohsumi, -1

机译：日本局部晚期或转移性乳腺癌患者中eribulin的安全性和有效性：上市后观察研究
8. Efficacy and Safety of Eribulin Compared with Control Therapy in Patients with Locally Advanced or Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials [O] . A Pagada, RK Mishra, P Bolshete, 2018

机译：与局部晚期或转移性乳腺癌患者的对照治疗相比，Eribulin的疗效和安全性：随机对照试验的荟萃分析

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study

摘要

著录项

相似文献

相关主题

期刊订阅